Gwendolyn Knowlton Binder-scholl - Net Worth and Insider Trading

Gwendolyn Knowlton Binder-scholl Net Worth

The estimated net worth of Gwendolyn Knowlton Binder-scholl is at least $1,974 dollars as of 2024-11-13. Gwendolyn Knowlton Binder-scholl is the Chief Technology Officer of Adaptimmune Therapeutics PLC and owns about 2,487 shares of Adaptimmune Therapeutics PLC (ADAP) stock worth over $1,974. Details can be seen in Gwendolyn Knowlton Binder-scholl's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Gwendolyn Knowlton Binder-scholl has not made any transactions after 2019-01-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Gwendolyn Knowlton Binder-scholl

Gwendolyn Knowlton Binder-scholl Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gwendolyn Knowlton Binder-scholl owns 1 companies in total, including Adaptimmune Therapeutics PLC (ADAP) .

Click here to see the complete history of Gwendolyn Knowlton Binder-scholl’s form 4 insider trades.

Insider Ownership Summary of Gwendolyn Knowlton Binder-scholl

Ticker	Comapny	Transaction Date	Type of Owner
ADAP	Adaptimmune Therapeutics PLC	2019-01-14	EVP & Adaptimmune LLC

Gwendolyn Knowlton Binder-scholl Latest Holdings Summary

Gwendolyn Knowlton Binder-scholl currently owns a total of 1 stock. Gwendolyn Knowlton Binder-scholl owns 2,487 shares of Adaptimmune Therapeutics PLC (ADAP) as of January 14, 2019, with a value of $1,974.

Latest Holdings of Gwendolyn Knowlton Binder-scholl

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ADAP	Adaptimmune Therapeutics PLC	2019-01-14	2,487	0.79	1,974

Holding Weightings of Gwendolyn Knowlton Binder-scholl

Gwendolyn Knowlton Binder-scholl Form 4 Trading Tracker

According to the SEC Form 4 filings, Gwendolyn Knowlton Binder-scholl has made a total of 0 transactions in Adaptimmune Therapeutics PLC (ADAP) over the past 5 years. The most-recent trade in Adaptimmune Therapeutics PLC is the sale of 1,514 shares on January 14, 2019, which brought Gwendolyn Knowlton Binder-scholl around $8,130.

Insider Trading History of Gwendolyn Knowlton Binder-scholl

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gwendolyn Knowlton Binder-scholl Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Gwendolyn Knowlton Binder-scholl Ownership Network

Ownership Network List of Gwendolyn Knowlton Binder-scholl

No Data

Ownership Network Relation of Gwendolyn Knowlton Binder-scholl

Gwendolyn Knowlton Binder-scholl Owned Company Details

What does Adaptimmune Therapeutics PLC do?

Who are the key executives at Adaptimmune Therapeutics PLC?

Gwendolyn Knowlton Binder-scholl is the EVP & Adaptimmune LLC of Adaptimmune Therapeutics PLC. Other key executives at Adaptimmune Therapeutics PLC include Chief Commercial Officer Cintia Piccina , Chief Medical Officer Elliot Norry , and Chief Operating Officer Bertrand William C Jr .

Adaptimmune Therapeutics PLC (ADAP) Insider Trades Summary

Over the past 18 months, Gwendolyn Knowlton Binder-scholl made no insider transaction in Adaptimmune Therapeutics PLC (ADAP). Other recent insider transactions involving Adaptimmune Therapeutics PLC (ADAP) include a net sale of 73,322 shares made by Adrian Rawcliffe , a net sale of 35,120 shares made by John Lunger , and a net sale of 32,818 shares made by Bertrand William C Jr .

In summary, during the past 3 months, insiders sold 0 shares of Adaptimmune Therapeutics PLC (ADAP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 245,864 shares of Adaptimmune Therapeutics PLC (ADAP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 245,864 shares.

Adaptimmune Therapeutics PLC (ADAP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Adaptimmune Therapeutics PLC Insider Transactions

No Available Data

Gwendolyn Knowlton Binder-scholl Mailing Address

Above is the net worth, insider trading, and ownership report for Gwendolyn Knowlton Binder-scholl. You might contact Gwendolyn Knowlton Binder-scholl via mailing address: 1903 Carpenter Street, Philadelphia Pa 19146.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.